151
Views
22
CrossRef citations to date
0
Altmetric
Original Research

Toward antituberculosis drugs: in silico screening of synthetic compounds against Mycobacterium tuberculosisl,d-transpeptidase 2

, , , , , , & show all
Pages 1147-1157 | Published online: 11 Mar 2016

References

  • BrennanPStructure, function, and biogenesis of the cell wall of Mycobacterium tuberculosisTuberculosis2003831–3919712758196
  • ErdemliSBGuptaRBishaiWRLamichhaneGAmzelLMBianchetMATargeting the cell wall of Mycobacterium tuberculosis: structure and mechanism of l,d-transpeptidase 2Structure201220122103211523103390
  • GuptaRLavollayMMainardiJLArthurMBishaiWRLamichhaneGThe Mycobacterium tuberculosis protein LdtMt2 is a nonclassicaltrans-peptidase required for virulence and resistance to amoxicillinNat Med201016446646920305661
  • ZumlaANahidPColeSTAdvances in the development of new tuberculosis drugs and treatment regimensNat Rev Drug Discov201312538840423629506
  • DreetzMHamacherJEllerJSerum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatinAntimicrob Agents Chemother19964011051098787889
  • WHO [webpage on the Internet]World Health Organization Global Tuberculosis Report 2015 Available from: http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1Accessed November 6, 2015
  • MatviiukTRodriguezFSaffonNDesign, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosisEur J Med Chem201370374824140915
  • SharmaSKMohanAMultidrug-resistant tuberculosisIndian J Med Res2004120435437615520486
  • JainRFFaulty prescription – an avoidable cause of MDR-TBIndian J Tuberc199845141143
  • ShowalterHDHDennyWAA roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatmentTuberculosis (Edinb)200888suppl 1S3S1718762151
  • CoxonGDCooperCBGillespieSHMcHughTDStrategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discoveryJ Infect Dis2012205suppl 2S258S26422448016
  • StanleySAGrantSSKawateTIdentification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screeningACS Chem Biol2012781377138422577943
  • LounnasVRitschelTKelderJMcGuireRBywaterRPFoloppeNCurrent progress in structure-based rational drug design marks a new mindset in drug discoveryComput Struct Biotechnol J20135e20130201124688704
  • PetrovaTChuprinaAParkeshRPushechnikovAStructural enrichment of HTS compounds from available commercial librariesMed Chem Commun20123571579
  • Accelrys Software IncDiscovery Studio Modeling Environment, Release 4.0San DiegoAccelrys Software Inc2007
  • FletcherRFunction minimization by conjugate gradientsComput J196472149154
  • LiWJLiDFHuYLZhangXEBiLJWangDCCrystal structure of l,d-transpeptidase LdtMt2 in complex with meropenem reveals the mechanism of carbapenem against Mycobacterium tuberculosisCell Res201323572873123588382
  • KimHSKimJImHNStructural basis for the inhibition of Mycobacterium tuberculosis l,d-transpeptidase by meropenem, a drug effective against extensively drug-resistant strainsActa Crystallogr D Biol Crystallogr201369pt 342043123519417
  • WuGRobertsonDHBrooksCLViethMDetailed analysis of grid-based molecular docking: a case study of CDOCKER-ACHARMm-based MD docking algorithmJ Comput Chem200324131549156212925999
  • TribouletSArthurMMainardiJLInactivation kinetics of a new target of -lactam antibioticsJ Biol Chem201128626227772278421543331
  • SauvageEKerffFTerrakMAyalaJACharlierPThe penicillin-binding proteins: structure and role in peptidoglycan biosynthesisFEMS Microbiol Rev200832223425818266856
  • WietzerbinJDasBCPetitJFLedererELeyh-BouilleMGhuysenJMOccurrence of D-alanyl-(D)-meso-diaminopimelic acid and meso-diaminopimelyl-meso-diaminopimelic acid interpeptide linkages in the peptidoglycan of MycobacteriaBiochemistry19741317347134764210702
  • LavollayMArthurMFourgeaudMThe peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by l,d-transpeptidationJ Bacteriol2008190124360436618408028
  • EnglandKBoshoffHIMAroraKMeropenem-Clavulanic acid shows activity against Mycobacterium tuberculosis in vivoAntimicrob Agents Chemother20125663384338722450968
  • WermuthCGGanellinCRLindbergPMitscherLAGlossary of terms used in medicinal chemistry (IUPAC recommendations 1998)Pure Appl Chem199870511291143
  • Van de WaterbeemdHGiffordEADMET in silico modelling: towards prediction paradise?Nat Rev Drug Discov20032319220412612645
  • ValerioLGJrIn silico toxicology for the pharmaceutical sciencesToxicol Appl Pharmacol2009241335637019716836
  • LecoqLBougaultCHugonnetJEDynamics induced by β-lactam antibiotics in the active site of Bacillus subtilis l,d-transpeptidaseStructure201220585086122579252